Intrathecal cell therapy with autologous stromal cells increases cerebral glucose metabolism and can offer a new approach to the treatment of Alzheimer's type dementia |
| |
| Institution: | 1. Neurosurgery Service, Puerta de Hierro-Majadahonda Hospital, Autonomous University, Madrid, Spain;2. Nuclear Medicine Service, Puerta de Hierro-Majadahonda Hospital, Autonomous University, Madrid, Spain;3. Neurology Service, Puerta de Hierro-Majadahonda Hospital, Autonomous University, Madrid, Spain;4. Department of Experimental Psychology, Faculty of Psychology, Complutense University, Madrid, Spain |
| |
| Abstract: | Background aimsAfter recent observations that intrathecal administration of autologous bone marrow mesenchymal stromal cells (MSCs) increases cerebral metabolism in patients with severe traumatic brain injury (TBI), we examined this type of cell therapy in Alzheimer's type dementia.MethodsThree patients with clinical diagnosis of Alzheimer's disease received every 3 months 100million autologous MSCs by intrathecal route, until a total dose of 300million.ResultsDuring cell therapy the patients showed arrest in neurological deterioration and two of them manifested clear improvement of previous symptoms. A global increase in cerebral glucose metabolism, measured using 18F-fluorodeoxyglucose positron emission tomography (18F-FDG-PET), was observed after every administration of cell therapy.ConclusionsOur present findings suggest that intrathecal administrations of autologous MSCs can be a new strategy for the treatment of Alzheimer's dementia. |
| |
| Keywords: | |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
